enGene Therapeutics Inc. Warrants (ENGNW) Stock Price
ENGNWStock
$0.18
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta1.30
ENGNW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-99.85%
Price vs S&P 500 (4W)-7.19%
VGM Score27.15
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENGNWenGene Therapeutics Inc. Warrants | — | — | D | $0.18 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About enGene Therapeutics Inc. Warrants
enGene Holdings is a clinical-stage biotechnology company developing non-viral gene therapies using its proprietary DDX gene delivery platform, which enables localized administration of genetic material to mucosal tissues and other organs. The company is initially targeting non-muscle invasive bladder cancer and is positioned to expand into additional disease areas with significant unmet clinical needs.